Article
Oncology
Li-Ting Liu, Huai Liu, Ying Huang, Jin-Hao Yang, Si-Yi Xie, Yuan-Yuan Li, Shan-Shan Guo, Bin Qi, Xiao-Yun Li, Dong-Ping Chen, Feng Jin, Xue-Song Sun, Zhen-Chong Yang, Sai-Lan Liu, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Fang Qiu, Qi Yang, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Rui Sun, Lin-Quan Tang, Hai-Qiang Mai
Summary: The efficacy and safety of concurrent adjuvant cisplatin-gemcitabine were compared with cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. The 3-year progression-free survival was significantly higher in the cisplatin-gemcitabine group (83.9%) compared to the cisplatin-fluorouracil group (71.5%). The adverse events were similar between the two groups. Therefore, cisplatin-gemcitabine could be considered as an adjuvant therapy option for patients with N2-3 nasopharyngeal carcinoma.
Article
Health Care Sciences & Services
Maria Ruiz-Minaya, Elsa Mendizabal-Vicente, Wenceslao Vasquez-Jimenez, Laura Perez-Burrel, Irene Aracil-Moreno, Carolina Agra-Pujol, Mireia Bernal-Claverol, Beatriz L. Martinez-Bernal, Mercedes Munoz-Fernandez, Melanie Morote-Gonzalez, Miguel A. Ortega, Santiago Lizarraga-Bonelli, Juan A. De Leon-Luis
Summary: Uterine sarcomas, rare and heterogeneous malignancies, exhibit different clinicopathological characteristics and prognosis based on histological subtypes. Due to the challenges of collecting a significant number of patients per year, multicentre or national registries are recommended for a more exhaustive analysis of this pathology.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Medicine, General & Internal
Yu-Pei Chen, Xu Liu, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guo-Qing Hu, Wei-Han Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xi-Cheng Wang, Liang-Fang Shen, Zheng-Zheng Liu, Jing Huang, Xiu-Ling Luo, Ling Li, Jian Zang, Qi Mei, Bao-Min Zheng, Dan Yue, Jing Xu, San-Gang Wu, Yan-Xia Shi, Yan-Ping Mao, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Rui Sun, Rui Guo, Yuan Zhang, Cheng Xu, Jia-Wei Lv, Ying Guo, Hui-Xia Feng, Ling-Long Tang, Fang-Yun Xie, Ying Sun, Jun Ma
Summary: This study found that adding oral metronomic capecitabine as adjuvant chemotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a good safety profile. These results support the potential role of metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma.
Article
Oncology
Rick Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, Nicolas Sauve, Enrico Clementel, Raquel Bar-Deroma, Cecile Le Pechoux, Saskia Litiere, Sandrine Marreaud, Najlaa Alyamani, Nicolaus H. J. Andratschke, Claudia Sangalli, Peter W. Chung, Aisha Miah, Coen Hurkmans, Alessandro Gronchi, Judith V. M. G. Bovee, Hans Gelderblom, Bernd Kasper, Damien Charles Weber, Sylvie Bonvalot
Summary: This study investigates the impact of radiotherapy compliance on survival outcomes in patients with retroperitoneal sarcoma, showing that patients who complied with radiotherapy requirements had a significantly higher abdominal recurrence-free survival rate.
Article
Oncology
Changying Shi, Yong Li, Li Geng, Weifeng Shen, Chengjun Sui, Binghua Dai, Jiongjiong Lu, Mianshun Pan, Jiamei Yang
Summary: This study aimed to investigate the efficacy of SBRT targeting suboptimal resection margin as adjuvant therapy in MVI-positive HCC. The results showed that SBRT group had significantly better DFS and OS compared to the surgery alone group.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Alexander M. M. Eggermont, Christian U. Blank, Mario Mandala, Georgina Long, Victoria G. Atkinson, Stephane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert
Summary: The study demonstrated that adjuvant pembrolizumab therapy can improve the 3.5-year distant metastasis-free survival in patients with resected high-risk stage III cutaneous melanoma, with a more significant effect in patients with PD-L1-positive tumors.
Article
Oncology
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandala, Georgina Long, Victoria G. Atkinson, Stephane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul C. Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Alexander M. M. Eggermont
Summary: The study showed that adjuvant pembrolizumab does not result in a clinically significant decrease in health-related quality of life (HRQOL) compared with placebo in patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting.
Article
Obstetrics & Gynecology
Siew-Fei Ngu, Hextan Y. S. Ngan, Karen K. L. Chan
Summary: Adjuvant and post-operative therapy are important approaches to reduce the risk of disease recurrence and improve potential for cure in gynecological cancers. They can be classified into systemic and locoregional treatment, which may include cytoreductive surgery, chemotherapy, PARPi maintenance therapy, or chemoradiation.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2022)
Article
Oncology
Orit Kaidar-Person, Catherine Fortpied, Sandra Hol, Caroline Weltens, Carine Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Femke van der Leij, Ernest Vonk, Mariacarla Valli, Nicola Weidner, Matthias Guckenberger, Eveline Koiter, Alain Fourquet, Harry Bartelink, Henk Struikmans, Philip Poortmans
Summary: This study analyzed the effects of different techniques of IM-MS lymph node irradiation on long-term outcomes in breast cancer patients. The results showed that using more individualized radiation therapy techniques can improve oncological outcomes without increasing the risk of late side effects.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
F. Petrelli, E. Rulli, R. Labianca, S. Lonardi, G. Rosati, K. Dotti, M. Ronzoni, N. Pella, V Pusceddu, M. Banzi, M. G. Zampino, M. Yasmina, P. Marchetti, M. Cantore, A. Zaniboni, L. Rimassa, L. Ciuffreda, D. Ferrari, V Zagonel, E. Maiello, A. Sobrero
Summary: The TOSCA study compared different durations of adjuvant chemotherapy in high-risk stage II and stage III colon cancer patients and found no significant difference in overall survival between the 3-month and 6-month treatment arms.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
Summary: The present study aimed to investigate the optimal timing of radiotherapy after mastectomy and adjuvant chemotherapy for high-risk breast cancer patients. The findings demonstrated that the timing of radiotherapy initiation significantly impacted patient outcomes.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr
Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.
Article
Medicine, General & Internal
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csoszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark McCleland, Elizabeth Bennett, Barbara Gitlitz, Heather Wakelee
Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.
Article
Oncology
Wai-Tong Ng, Cheuk-Wai Choi, Barton But, Roger K. C. Ngan, Stewart Tung, Ashley C. Cheng, Dora L. W. Kwong, Tai-Xiang Lu, Anthony T. C. Chan, Harry Yiu, Sarah Lee, Frank Wong, Kam-Tong Yuen, Richard J. Chappell, Anne W. M. Lee
Summary: The combination of cisplatin-based induction or adjuvant chemotherapy with concurrent chemoradiotherapy has been found to improve overall survival in patients with locoregionally advanced nasopharyngeal carcinoma. The optimal platinum doses for the concurrent and induction/adjuvant phases were determined to be 160 mg/m(2) and 260 mg/m(2) respectively.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
V. Murthy, P. Maitre, M. Singh, M. Pal, A. Arora, L. Pujari, A. Kapoor, H. Pandey, R. Sharma, D. Gudipudi, A. Joshi, K. Prabhash, V. Noronha, S. Menon, P. Mehta, G. Bakshi, G. Prakash
Summary: This study aims to evaluate the efficacy and safety of adjuvant radiotherapy in high-risk muscle-invasive bladder cancer (MIBC) patients after radical cystectomy and chemotherapy. The ongoing BART trial is comparing the outcomes of adjuvant radiotherapy versus observation in high-risk MIBC patients. The importance of this trial lies in determining whether adjuvant radiotherapy after standard treatment can safely reduce pelvic recurrences and potentially impact the survival of high-risk MIBC patients.
Article
Endocrinology & Metabolism
Silvia Baggio, Rossana Di Paola, Stefano Zaffagnini, Stefania Fino, Ricciarda Raffaelli, Massimo Franchi
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
(2019)
Article
Oncology
Vincenzo D. Mandato, Federica Torricelli, Stefano Palomba, Stefano Uccella, Debora Pirillo, Gino Ciarlini, Pierandrea De Iaco, Emilio Lucia, Giorgio Giorda, Antonino Ditto, Fabio Ghezzi, Francesca Sanseverino, Massimo Franchi, Giuseppe Bifulco, Valentina Mastrofilippo, Martino Abrate, Lorenzo Aguzzoli, Giovanni B. La Sala
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2019)
Letter
Obstetrics & Gynecology
Rami Mohamed Bakr Barakat, Simone Garzon, Antonio Simone Lagana, Massimo Franchi, Fabio Ghezzi
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2020)
Article
Surgery
Massimo Franchi, Simone Garzon, Pier Carlo Zorzato, Antonio Simone Lagana, Jvan Casarin, Luisa Locantore, Ricciarda Raffaelli, Fabio Ghezzi
MINIMALLY INVASIVE THERAPY & ALLIED TECHNOLOGIES
(2020)
Article
Oncology
Pier Carlo Zorzato, Gian Franco Zannoni, Riccardo Tudisco, Tina Pasciuto, Andrea Di Giorgio, Massimo Franchi, Giovanni Scambia, Anna Fagotti
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2020)
Review
Biochemistry & Molecular Biology
Antonio Simone Lagana, Simone Garzon, Martin Goette, Paola Vigano, Massimo Franchi, Fabio Ghezzi, Dan C. Martin
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Obstetrics & Gynecology
Martina Montagnana, Marco Benati, Angela Tagetti, Ricciarda Raffaelli, Elisa Danese, Nicoletta Zatti, Denise Marcon, Lorella Branz, Chiara Micheli, Massimo Franchi, Cristiano Fava, Giuseppe Lippi
Summary: This study confirms the roles of circ_100219 and miR-135b in physiological pregnancy, with decreased expression of circ_100219 and increased expression of miR-135b in the serum and exosomes of second trimester pregnant women compared to nonpregnant women. There is a significant negative correlation between the expression levels of circ_100219 and miR-135b in both serum and exosomes. Nonpregnant women have significantly higher circ_100219:miR-135b ratios compared to pregnant women in both serum and exosomes.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
(2021)
Article
Obstetrics & Gynecology
Massimo Franchi, Francesca Parissone, Cecilia Lazzari, Simone Garzon, Antonio Simone Lagana, Ricciarda Raffaelli, Antonella Cromi, Fabio Ghezzi
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2020)
Editorial Material
Surgery
Antonio Simone Lagana, Simone Garzon, Ricciarda Raffaelli, Giuseppe Gullo, Massimo Franchi
JOURNAL OF INVESTIGATIVE SURGERY
(2021)
Editorial Material
Surgery
Antonio Simone Lagana, Simone Garzon, Jvan Casarin, Ricciarda Raffaelli, Antonella Cromi, Massimo Franchi, Fabio Ghezzi
JOURNAL OF INVESTIGATIVE SURGERY
(2021)
Editorial Material
Surgery
Antonio Simone Lagana, Simone Garzon, Ricciarda Raffaelli, Helena Ban Frangez, David Lukanovic, Massimo Franchi
JOURNAL OF INVESTIGATIVE SURGERY
(2021)
Letter
Obstetrics & Gynecology
Massimo Franchi, Francesca Parissone, Cecilia Lazzari, Simone Garzon, Antonio Simone Lagana, Ricciarda Raffaelli, Antonella Cromi, Fabio Ghezzi
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2020)
Article
Medical Laboratory Technology
Federica Bortolotti, Ricciarda Raffaelli, Nicoletta Di Simone, Michela Semprebon, Mariateresa Mirandola, Chiara Simonetto, Francesca De Marchi, Maria Teresa Trevisan, Giovanna Carli, Romolo M. Dorizzi, Giovanni Scambia, Massimo Franchi, Franco Tagliaro
CLINICA CHIMICA ACTA
(2020)
Article
Oncology
Gabriella Ferrandina, Cynthia Aristei, Pietro Raimondo Biondetti, Ferdinando Carlo Maria Cananzi, Paolo Casali, Francesca Ciccarone, Nicoletta Colombo, Alessandro Comandone, Renzo Corvo', Pierandrea De Iaco, Angelo Paolo Dei Tos, Vittorio Donato, Marco Fiore, Franchi, Angiolo Gadducci, Alessandro Gronchi, Stefano Guerriero, Amato Infante, Franco Odicino, Tommaso Pirronti, Vittorio Quagliuolo, Roberta Sanfilippo, Antonia Carla Testa, Gian Franco Zannoni, Giovanni Scambia, Domenica Lorusso
EUROPEAN JOURNAL OF CANCER
(2020)
Review
Endocrinology & Metabolism
Francesca Parissone, Mairi Pucci, Emanuela Meneghelli, Orsetta Zuffardi, Rossana Di Paola, Stefano Zaffagnini, Massimo Franchi, Elisabetta Santangelo, Gaetano Cantalupo, Paolo Cavarzere, Franco Antoniazzi, Giorgio Piacentini, Rossella Gaudino
INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY
(2020)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)